Evidence map›Paper›PMID 39950551›Full record

ArticleAdvanced healthcare materials2025

Pincer-Type Pt(II)-NHC Antibody-Drug Conjugate for HER-2-Targeted Chemoimmunotherapy.

Tao Huang, Wan-Qiong Huang, Gui-Feng Huang, Xiao-Long Wei, Yong-Liang Huang, Tao Liu, Yungen Liu, Wen-Xiu Ni, Chi-Ming Che

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Advanced healthcare materials, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Review
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Tao HuangDepartment of Medicinal Chemistry, Shantou University Medical College, Shantou, Guangdong, 515041, P. R. China.ORCID 0000-0002-6231-342X
Wan-Qiong HuangDepartment of Pathology, Cancer Hospital of Shantou University Medical College, Shantou, Guangdong, 515041, P. R. China.ORCID 0000-0003-1837-9322
Gui-Feng HuangDepartment of Medicinal Chemistry, Shantou University Medical College, Shantou, Guangdong, 515041, P. R. China.ORCID 0009-0006-0843-1173
Xiao-Long WeiDepartment of Pathology, Cancer Hospital of Shantou University Medical College, Shantou, Guangdong, 515041, P. R. China.
Yong-Liang HuangDepartment of Medicinal Chemistry, Shantou University Medical College, Shantou, Guangdong, 515041, P. R. China.
Tao LiuDepartment of Medicinal Chemistry, Shantou University Medical College, Shantou, Guangdong, 515041, P. R. China.
Yungen LiuDepartment of Chemistry, Southern University of Science and Technology, Shenzhen, Guangdong, 518055, P. R. China.
Wen-Xiu NiDepartment of Medicinal Chemistry, Shantou University Medical College, Shantou, Guangdong, 515041, P. R. China.ORCID 0000-0002-2370-6300
Chi-Ming CheState Key Laboratory of Synthetic Chemistry and Department of Chemistry, The University of Hong Kong, Hong Kong, P. R. China.ORCID 0000-0002-2554-7219

Funding

Guangdong Basic and Applied Basic Research Foundation 2019B030302009Guangdong Basic and Applied Basic Research Foundation 2023A1515011759Guangdong Basic and Applied Basic Research Foundation 2023A1515030234Guangdong Basic and Applied Basic Research Foundation 2023A1515220204Laboratory for Synthetic Chemistry and Chemical BiologyPreparation and Application of Ordered Structural Materials of Guangdong Province 2023B1212120011
6 · The paper itself

Abstract

Platinum-based chemotherapy drugs play an indispensable role in clinical cancer treatment, but exhibit considerable side effects due to their non-specific mechanism of killing cancer cells and normal cells. In this regard, the use of antibodies conjugated to anti-cancer platinum complexes will enable better differentiation of cancer cells from normal cells. Here, six pincer-platinum(II) NHC (N-heterocyclic carbene) complexes are reported, one of which has an amino group on the N-alkyl group of the NHC ligand. This platinum(II) complex is used as the payload for platinum(II)-based antibody-drug conjugate (ADC) targeting human epidermal growth factor receptor 2 (HER-2). Notably, this ADC can specifically bind to the HER-2 antigen, distinguish target cells from non-target cells, and exhibit good anti-tumor activity in vitro and in vivo.

Indexed as

Antineoplastic AgentsErb-b2 Receptor Tyrosine KinasesHeterocyclic CompoundsImmunoconjugatesImmunotherapyOrganoplatinum CompoundsPlatinumAnimalsCell Line, TumorFemaleHumansMethaneMiceMice, Inbred BALB CMice, NudeAntineoplastic AgentscarbeneERBB2 protein, humanErb-b2 Receptor Tyrosine KinasesHeterocyclic CompoundsImmunoconjugatesMethaneOrganoplatinum CompoundsPlatinumantibody‐drug conjugateHER‐2 targetedimmunogenic cell deathnecroptosisPt(II) NHC

Identifiers

PMID39950551
PMCPMC11973945

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.